Zura Bio Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZURA research report →
Range $20 – $20
Price Chart
About the company
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
- CEO
- Sandeep C. Kulkarni
- IPO
- 2023
- Employees
- 40
- HQ
- Henderson, NV, US
Get TickerSpark's AI analysis on ZURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $89.63M
- P/E
- -0.83
- PEG
- 0.02
- P/S
- 0.00
- P/B
- 0.67
- EV/EBITDA
- 1.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.97%
- ROIC
- -56.63%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-75,246,000
- Net Income
- $-68,650,000-31.0%
- EPS
- $-1.06-76.7%
- OCF Growth
- -130.9%
- FCF Growth
- -130.6%
- 52W High
- $7.44
- 52W Low
- $0.92
- 50D MA
- $3.63
- 200D MA
- $4.98
- Beta
- -0.04
- RSI (14)
- 24
- Avg Volume
- 4.41M
No earnings-call transcripts are available for ZURA yet.
- Free Float
- 47.3%
- Shares Outstanding
- 96.33M
- Float Shares
- 45.58M
of shares held by institutions
100 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Montanova Capital, LLC | 9.44M | ▲ 376.00K |
| Venrock Adviser, LLC | 6.43M | 0 |
| Mpm Bioimpact LLC | 4.47M | ▲ 4.47M |
| Great Point Partners LLC | 4.22M | 0 |
| Braidwell LP | 3.98M | ▼ 8.69K |
| Siren, L.L.C. | 3.73M | 0 |
| Blackrock, Inc. | 3.70M | ▲ 85.24K |
| Commodore Capital LP | 3.25M | 0 |
| Adage Capital Partners Gp, L.L.C. | 2.75M | 0 |
| Saturn V Capital Management LP | 2.10M | ▲ 1.36M |
| Qvt Financial LP | 1.90M | ▲ 584.56K |
| Adar1 Capital Management, LLC | 1.76M | ▲ 1.13M |
Held by 43 ETFs
Biggest fund positions in ZURA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Mathew Marlyn Teresa | other | 0 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 0 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 0 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 0 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 0 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 0 |
| Jun 17, 26 | Jarrett Jennifer | other | 51,000 |
| Jun 17, 26 | Thiara Parvinder | other | 51,000 |
| Jun 17, 26 | Schoch Steven J | other | 51,000 |
| Jun 17, 26 | Nirula Ajay | other | 51,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZURA coverage
Recent articles, reports, and earnings notes.
No research on ZURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZURA report →Zura Bio Limited (ZURA) Securities Investigation Notice - Levi & Korsinsky
gurufocus.com · Nov 16
Zura Bio Limited (ZURA) Securities Investigation Notice - Levi & Korsinsky
prnewswire.com · Nov 16
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Zura Bio Limited (ZURA)
globenewswire.com · Nov 12
ZURA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zura Bio Limited
prnewswire.com · Nov 10
ZURA Investors Have Opportunity to Join Zura Bio Limited Fraud Investigation with SBS Law
businesswire.com · Nov 10
Zura Bio Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zura Bio Limited (ZURA)
prnewswire.com · Nov 9
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
gurufocus.com · Nov 9
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
businesswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.